SCHEMBL6784867

SCHEMBL6784867

CCOC(=O)c1cc(NS(=O)(=O)c2ccccc2)ccc1NC(=O)/C=C(/C)c1ccc2ccccc2c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TERT O14746 5/20 0.55
AR P10275 1/20 0.49
KMT2A Q03164 2/20 0.48
TSHR P16473 1/20 0.48
SMN1; SMN2 Q16637 4/20 0.47
LMNA P02545 4/20 0.47
MEN1 O00255 1/20 0.47
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2D6 P10635 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
MCL1 Q07820 1/20 0.46
GPR27 Q9NS67 1/20 0.46
HIF1A Q16665 1/20 0.46
ALDH1A1 P00352 3/20 0.44
NPSR1 Q6W5P4 1/20 0.44
GAA P10253 1/20 0.44
HPGD P15428 1/20 0.43
MAPK1 P28482 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6788177 0.90 TERT (0.55) TERTARTSHRSMN1; SMN2LMNA
SCHEMBL6786986 0.89 TERT (0.67) TERTKMT2ASMN1; SMN2LMNAMEN1
SCHEMBL6784482 0.88 TERT (0.53) TERTARLMNACYP1A2CYP2C19
SCHEMBL6783765 0.85 TERT (0.59) TERTKMT2ASMN1; SMN2LMNAMEN1
SCHEMBL6786322 0.85 TERT (0.56) TERTKMT2ASMN1; SMN2LMNAMEN1
SCHEMBL6791830 0.84 TERT (0.56) TERTKMT2ASMN1; SMN2LMNAMEN1
SCHEMBL6790238 0.83 TERT (0.67) TERTKMT2ASMN1; SMN2LMNAMEN1
SCHEMBL6786590 0.82 TERT (0.55) TERTKMT2ASMN1; SMN2LMNAMEN1
SCHEMBL6788362 0.81 TERT (0.53) TERTKMT2ALMNACYP1A2CYP2D6
SCHEMBL6784598 0.81 TERT (0.53) TERTKMT2ASMN1; SMN2LMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6727250-B2 ADMINISTERING COMPOUNDS SUCH AS TRANS-3-(NAPHTH-2-YL)-BUT-2-ENOIC ACID-N-(2-CARBOXY-PHENYL)-AMIDE OR LIKE FOR THERAPY OF CONDITIONS ASSOCIATED WITH INCREASED TELOMERASE ACTIVITY, E.G. TUMOUR DISEASES BOEHRINGER INGELHEIM PHARMA KG (DE) 2004-04-27 US disclosed
US-20020099089-A1 Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2002-07-25 US disclosed
US-6362210-B1 ANTITUMOR, ANTICANCER AGENT BOEHRINGER INGELHEIM PHARMA KG (DE) 2002-03-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020099089-A1 Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation TERT, NAT1, POT1 TERT 1/4885AR 931/4885KMT2A 490/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.